ESTRO meets Asia 2024 - Abstract Book

S143

Interdisciplinary – Gynaecological

ESTRO meets Asia 2024

[13] COATE L, JOHN, T, TSAO, MS, ET AL. . Molecular predictive and prognostic markers in non-small-cell lung cancer [J]. LANCET ONCOL, 2009, 10 (10): 1001-10. [14] KEYS H, BUNDY, BN, STEHMAN, FB, ET AL Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma [J]. NEW ENGL J MED, 1999, 340 (15): 1154-61. [15] LI F, MEI F, YIN S, et al. Improving the efficacy and safety of concurrent chemoradiotherapy by neoadjuvant chemotherapy: a randomized controlled study of locally advanced cervical cancer with a large tumor [J]. J Gynecol Oncol, 2023. [16] TORRES M A, JHINGRAN A, THAMES H D, JR., et al. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment [J]. Int J Radiat Oncol Biol Phys, 2008, 70(1): 118-25. [17] PETERS W, LIU, PY, BARRETT, RJ, ET AL. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix [J]. J CLIN ONCOL, 2023, 41 (29): 4605-4612. . [18] SHAVERDIAN N, GONDI V, SKLENAR K L, et al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer [J]. Int J Radiat Oncol Biol Phys, 2013, 86(3): 562-8. [19] KOTHA N V, WILLIAMSON C W, MARRA K V, et al. Incomplete cisplatin regimens in chemoradiation and its effect on outcomes for locally advanced cervical cancer [J]. Int J Gynecol Cancer, 2022, 32(12): 1540-8. [20] FU J, WANG W, WANG Y, et al. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer [J]. Radiat Oncol, 2019, 14(1): 146. [21] DUENAS-GONZALEZ A, ZARBA J J, PATEL F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix [J]. J Clin Oncol, 2011, 29(13): 1678-85. [22] PETRELLI F, DE STEFANI A, RASPAGLIESI F, et al. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis [J]. Gynecol Oncol, 2014, 134(1): 166 71. [23] KUMAR L, HARISH P, MALIK P S, et al. Chemotherapy and targeted therapy in the management of cervical cancer [J]. Curr Probl Cancer, 2018, 42(2): 120-8. [24] MA S, WANG J, HAN Y, et al. Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials [J]. Gynecol Oncol, 2019, 154(1): 246-52. [25] MILESHKIN L R, MOORE K N, BARNES E H, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial [J]. Lancet Oncol, 2023, 24(5): 468-82. [26] TANGJITGAMOL S, THARAVICHITKUL E, TOVANABUTRA C, et al. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial [J]. J Gynecol Oncol, 2019, 30(4): e82. [27] DUENAS-GONZALEZ A, ORLANDO M, ZHOU Y, et al. Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial [J]. Gynecol Oncol, 2012, 126(3): 334-40. [28] MATSUO K, MANDELBAUM R S, MACHIDA H, et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix [J]. J Gynecol Oncol, 2018, 29(6): e91. [29] RONSINI C, ANCHORA L P, RESTAINO S, et al. The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients [J]. Gynecol Oncol, 2021, 162(2): 299-307.

203

Proffered Paper

Moderated Hypofractionated Adaptive Radiotherapy in Cervical Cancer: A Prospective 1 Clinical Trial